Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation InhibitorsAnnachiara Gandini, María Laura Bolognesi, Alessandra Feoli et al.|Journal of Medicinal Chemistry|2018Cited by 104
Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosaAlonso Sánchez-Cruz, Catalina Hernández‐Sánchez, Beatriz Villarejo‐Zori et al.|Molecular Neurodegeneration|2018Cited by 42
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agentsIrene G. Salado, Ana Martı́nez, Josefa Zaldívar-Díez et al.|European Journal of Medicinal Chemistry|2017Cited by 36
Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosaMiguel Marchena, Enrique J. de la Rosa, Beatriz Villarejo‐Zori et al.|Journal of Enzyme Inhibition and Medicinal Chemistry|2017Cited by 25
Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic FateJosefa Zaldívar-Díez, Ana Martı́nez, Lingling Li et al.|Journal of Medicinal Chemistry|2019Cited by 25